Table 1

Patients' characteristics and treatment outcomes of previously untreated and relapsed/refractory multiple myeloma


ORR
 CR/VGPR
 PFS
 OS


Characteristics
 Total patients (N = 42)
 No. of
Patients
%
 p-value
 No. of
patients
 p-value
 HR
 95% CI
 p-value
 HR
 95% CI
 p-value
Age (years), median (range)
 62,(36-75)









     ≤ 60
 17
 15(94)
 0.83
 9(56.3)
 0.45
 2.95
 0.98-8.81
 0.05
 0.81
 0.09-7.27
 0.85
     > 60
 25
 23(92)
17(68)




Sex










     Male
 21
 18(85.7)
 0.79
 13(65)
 0.91
 0.77
 0.25-2.38
 0.65
 2.06
 0.34-12.68
 0.44
     Female
 21
 20(95.2)
14(66.7)






Prior treatment










     Yes
 29
 26(92.6)
 0.95
 19(67.9)
 0.69
 3.68
 0.91-10.28
 0.06
 0.87
 0.96-7.88
 0.9
     No
 13
 12(92.3)
8(61.5)






International staging system










     I, II
 8, 18
 24(92.3)
 0.97
 15(57.7)
 0.93
 6.30
 0.73-54.01
 0.09
 2.22
 0.20-24.57
 0.51
     III
 13
 12(92.3)
8(61.5)






     No data
 3









M-protein subtype










     IgG, IgA, IgM
 23, 8, 1
 27(87.1)
 0.32
 19(61.3)
 0.86
 3.19
 0.64-15.91
 0.16
 1.21
 0.13-11.65
 0.87
     Kappa, Lamda
 3, 6
 9(100)
6(66.7)






     Unknown type
 1









Serum creatinine level










     < 2 mg/dl
 34
 31(91.2)
 0.43
 22(64.7)
 0.57
 0.74
 0.08-6.72
 0.79
 0.03
 0.01-856.9
 0.50
     ≥ 2 mg/dl
 8
 7(100)
4(57.2)






Serum β2 M level, μg/ml










     ≤ 5
 26
 24(92.3)
 0.53
 17(65.4)
 0.79
 4.89
 0.55-43.88
 0.16
 1.97
 0.18-21.81
 0.58
     > 5
 13
 11(84.6)
8(61.5)






     No data
 3









Response to treatment










     Yes
 38
 -
 -
 -
 -
 0.15
 0.04-0.61
 0.01
 0.03
 0.01-0.35
 0.01
     No
 3









CR/VGPR










     Yes
 26
 -
 -
 -
 -
 0.14
 0.04-0.47
 0.01
 0.21
 0.03-1.48
 0.12
     No
 15









Niparuck et al. Journal of Hematology & Oncology 2010 3:1   doi:10.1186/1756-8722-3-1

Open Data